Amylyx Pharmaceuticals Advances AMX0318 as Long-Acting GLP-1 Receptor Antagonist for Rare Diseases

Reuters01-08

<a href="https://laohu8.com/S/AMLX">Amylyx Pharmaceuticals</a> Advances AMX0318 as Long-Acting GLP-1 Receptor Antagonist for Rare Diseases

Amylyx Pharmaceuticals Inc. has announced the nomination of AMX0318 as a novel, long-acting GLP-1 receptor antagonist development candidate, identified in collaboration with Gubra A/S. AMX0318 is being developed for post-bariatric hypoglycemia $(PBH)$ and other rare diseases. The candidate has completed extensive preclinical evaluation, demonstrating robust stability, solubility, potency, in vivo pharmacokinetics and pharmacodynamics, and tolerability. Amylyx expects to advance AMX0318 into investigational new drug $(IND)$-enabling studies later this year, with an IND submission targeted for 2027, pending successful study completion. The results have not yet been presented; further development is ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260108102624) on January 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601664633?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601664633","market":"fut","top_or_hot":-1,"title":"Amylyx Pharmaceuticals Advances AMX0318 as Long-Acting GLP-1 Receptor Antagonist for Rare Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AMLX\">Amylyx Pharmaceuticals</a> Advances AMX0318 as Long-Acting GLP-1 Receptor Antagonist for Rare Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Amylyx Pharmaceuticals Inc. has announced the nomination of AMX0318 as a novel, long-acting GLP-1 receptor antagonist development candidate, identified in collaboration with Gubra A/S. AMX0318 is being developed for post-bariatric hypoglycemia <a href=\"https://laohu8.com/S/PBH\">$(PBH)$</a> and other rare diseases. The candidate has completed extensive preclinical evaluation, demonstrating robust stability, solubility, potency, in vivo pharmacokinetics and pharmacodynamics, and tolerability. Amylyx expects to advance AMX0318 into investigational new drug <a href=\"https://laohu8.com/S/IND\">$(IND)$</a>-enabling studies later this year, with an IND submission targeted for 2027, pending successful study completion. The results have not yet been presented; further development is ongoing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260108102624) on January 08, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amylyx Pharmaceuticals Advances AMX0318 as Long-Acting GLP-1 Receptor Antagonist for Rare Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmylyx Pharmaceuticals Advances AMX0318 as Long-Acting GLP-1 Receptor Antagonist for Rare Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-08 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AMLX\">Amylyx Pharmaceuticals</a> Advances AMX0318 as Long-Acting GLP-1 Receptor Antagonist for Rare Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Amylyx Pharmaceuticals Inc. has announced the nomination of AMX0318 as a novel, long-acting GLP-1 receptor antagonist development candidate, identified in collaboration with Gubra A/S. AMX0318 is being developed for post-bariatric hypoglycemia <a href=\"https://laohu8.com/S/PBH\">$(PBH)$</a> and other rare diseases. The candidate has completed extensive preclinical evaluation, demonstrating robust stability, solubility, potency, in vivo pharmacokinetics and pharmacodynamics, and tolerability. Amylyx expects to advance AMX0318 into investigational new drug <a href=\"https://laohu8.com/S/IND\">$(IND)$</a>-enabling studies later this year, with an IND submission targeted for 2027, pending successful study completion. The results have not yet been presented; further development is ongoing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260108102624) on January 08, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL2M7hcL:1","article_id":"2601664633","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601664633","pubTimestamp":1767873645,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Amylyx Pharmaceuticals Inc. has announced the nomination of AMX0318 as a novel, long-acting GLP-1 receptor antagonist development candidate, identified in collaboration with Gubra A/S. AMX0318 is being developed for post-bariatric hypoglycemia  and other rare diseases. The candidate has completed extensive preclinical evaluation, demonstrating robust stability, solubility, potency, in vivo pharmacokinetics and pharmacodynamics, and tolerability. Amylyx expects to advance AMX0318 into investigational new drug -enabling studies later this year, with an IND submission targeted for 2027, pending successful study completion. The results have not yet been presented; further development is ongoing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advic","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","AMLX":"Amylyx Pharmaceuticals"},"translate_title":"Amylyx Pharmaceuticals推进AMX0318作为治疗罕见疾病的长效GLP-1受体拮抗剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMLX":0.9},"content_text":"Amylyx Pharmaceuticals Advances AMX0318 as Long-Acting GLP-1 Receptor Antagonist for Rare Diseases\n    \n\n        Amylyx Pharmaceuticals Inc. has announced the nomination of AMX0318 as a novel, long-acting GLP-1 receptor antagonist development candidate, identified in collaboration with Gubra A/S. AMX0318 is being developed for post-bariatric hypoglycemia $(PBH)$ and other rare diseases. The candidate has completed extensive preclinical evaluation, demonstrating robust stability, solubility, potency, in vivo pharmacokinetics and pharmacodynamics, and tolerability. Amylyx expects to advance AMX0318 into investigational new drug $(IND)$-enabling studies later this year, with an IND submission targeted for 2027, pending successful study completion. The results have not yet been presented; further development is ongoing.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260108102624) on January 08, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601664633","isCrawlerRequest":true}